Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR".
Zydus Lifesciences Limited Press Release Jul 23 2026
Filed with NSE · · 5 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received approval for a Phase III clinical trial of Desidustat for patients with sickle cell disease, in collaboration with ICMR. The trial aims to evaluate the efficacy and safety of Desidustat oral tablets in treating anemia in sickle cell disease patients. This follows the successful completion of a Phase II proof-of-concept trial that demonstrated positive outcomes. The study will enroll a specific number of patients diagnosed with the disease and is part of Zydus' commitment to addressing unmet medical needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jul 03 2026
- Press Release May 28 2026
- Zydus Cancer Hospital, Ahmedabad marks 200+ Stereotactic Radiotherapy (SRT)/SRS for Brain Tumours
- Press Release May 19 2026
- Press Release May 06 2026
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Aug 01 2026
- Zydus Lifesciences Limited Press Release Aug 04 2026
- Zydus Lifesciences Limited Press Release Aug 11 2026
- Zydus Hospitals Sets New Benchmarks in High-Risk Pregnancy and Complex Gynaecological Care
- Zydus Lifesciences Limited Press Release Aug 21 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences